Treg-derived IκBζ promotes their conversion into Th2-like effectors and drives type 2 inflammation via BATF

This study identifies IκBζ as a critical molecular switch that reprograms regulatory T cells into Th2-like effectors by modulating BATF expression, thereby driving systemic type 2 inflammation and disrupting peripheral immune tolerance.

The Gist

The Big Picture: When the Peacekeepers Turn into Agitators

Imagine your body is a bustling city. In this city, you have a special police force called Regulatory T cells (Tregs). Their job is to be the "peacekeepers." They walk around making sure the other immune cells (the "traffic cops" and "firefighters") don't overreact, cause traffic jams (inflammation), or attack innocent civilians (your own healthy tissues). They keep the city calm and safe.

This study discovered a specific "switch" inside these peacekeepers called IκBζ (pronounced I-kappa-B-zeta). The researchers found that when this switch gets stuck in the "ON" position, the peacekeepers don't just stop working—they actually transform into troublemakers. They start causing chaos, specifically a type of inflammation known as Type 2 inflammation (which is behind allergies, asthma, and eczema).

The Story of the "Stuck Switch" (Overexpression)

The scientists created a group of mice where they forced the IκBζ switch to stay permanently "ON" inside the peacekeeper cells.

• What happened? The peacekeepers started multiplying like crazy, but they weren't doing their job anymore. Instead of calming things down, they started shouting orders to build "Type 2" defenses.
• The Result: The mice developed swollen lymph nodes and spleens (like a city with too many police cars clogging the streets). More importantly, their lungs, skin, and gut started getting inflamed.
• The Culprit: The lungs were hit the hardest. The mice developed thick mucus (like a foggy, sticky city), fibrosis (scarring), and a massive influx of allergy-related cells.
• The B-Cell Connection: Because the peacekeepers were shouting "Type 2" signals, the body's antibody factories (B cells) went into overdrive. They started mass-producing IgE antibodies (the kind that cause severe allergic reactions) and even started attacking the body's own tissues (autoimmunity).

The Analogy: Imagine the peacekeepers (Tregs) suddenly decided to become a riot squad. Instead of stopping the fire, they started throwing gasoline on it, telling the firefighters to spray water everywhere, and causing the whole city to panic.

The Secret Mechanism: The "Manager" and the "Foreman"

How did the peacekeepers turn into rioters? The study found a specific chain of command:

1. IκBζ (The Manager): This is the protein that was stuck "ON."
2. BATF (The Foreman): IκBζ doesn't know how to build things itself, so it hires a foreman named BATF.
3. The Construction: The Manager (IκBζ) tells the Foreman (BATF) to go to the construction site of the cell's DNA and start building Th2 cytokines (specifically IL-4 and IL-13). These are the chemical signals that cause allergies and mucus production.

The Analogy: IκBζ is like a boss who walks into a quiet office and tells the foreman, "Stop doing paperwork. Start building a giant rollercoaster!" The foreman (BATF) listens, and suddenly the office is filled with rollercoasters (allergic inflammation) instead of paperwork (immunity regulation).

The "Off" Switch Experiment (Deletion)

To prove this was true, the scientists did the opposite experiment. They took a group of mice and removed the IκBζ switch entirely from the peacekeepers.

• The Scenario: They exposed these mice to IL-33, a chemical signal released when tissue is damaged (like a "Help! We're under attack!" siren). Usually, this siren makes the peacekeepers expand and sometimes get confused, turning them into the "riot squad" described above.
• The Result: In mice without the IκBζ switch, the peacekeepers stayed calm. They didn't turn into rioters. They didn't produce the allergy chemicals.
• The Surprise: Because the peacekeepers stayed true to their job, the inflammation in the lungs was actually much lower than in normal mice. The "riot" never started.

The Analogy: When the "Help!" siren (IL-33) went off, the peacekeepers in normal mice panicked and started a riot. But the peacekeepers without the IκBζ switch stayed calm, kept the peace, and actually helped the city recover faster.

Why Does This Matter?

This discovery is a game-changer for understanding diseases like asthma, eczema, and allergies.

1. The Double-Edged Sword: We used to think that expanding our "peacekeeper" cells (Tregs) was always a good thing to treat inflammation. This study says: Be careful. If you expand them without controlling the IκBζ switch, you might accidentally create a population of cells that causes the very inflammation you are trying to stop.
2. New Targets: The protein IκBζ and its partner BATF are now identified as critical "switches." If we can find drugs to turn off IκBζ in people with severe allergies or asthma, we might be able to stop the peacekeepers from turning into rioters.
3. The Lung Connection: The study showed that the lungs are the most sensitive organ to this switch. This explains why asthma (a lung disease) is so often driven by these specific types of immune confusion.

Summary in One Sentence

This paper reveals that a specific protein called IκBζ acts as a dangerous switch that can trick the body's immune "peacekeepers" into becoming "allergy-causing rioters," and turning this switch off could be the key to stopping severe allergic inflammation.

Technical Summary

1. Problem Statement

Regulatory T cells (Tregs) are essential for maintaining peripheral immune tolerance and tissue homeostasis. While they possess plasticity, particularly in tissue-resident subsets (characterized by ST2/IL-33R expression), the molecular mechanisms governing their conversion into pathogenic effector cells under inflammatory conditions remain poorly defined. Specifically, the role of the NF-κB transcriptional cofactor IκBζ (encoded by Nfkbiz) in Treg cell stability, plasticity, and function in the context of Type 2 inflammation (e.g., asthma, atopic dermatitis) was unknown. Previous studies suggested IκBζ might repress FoxP3 or be required for Treg function in colitis, but its specific role in driving Th2-like reprogramming was unclear.

2. Methodology

The authors employed a comprehensive gain-of-function and loss-of-function approach using mouse models, combined with multi-omics and immunological assays:

• Mouse Models:
  • Gain-of-Function: Generation of a Treg-specific IκBζ overexpression model (Nfkbiz OEΔTreg) using a doxycycline-inducible system controlled by FoxP3-Cre. Notably, expression was found to be constitutive even without doxycycline.
  • Loss-of-Function: Generation of a Treg-specific IκBζ knockout model (Nfkbiz KOΔTreg) by crossing Nfkbiz floxed mice with FoxP3-Cre mice.
• In Vivo Challenges:
  • Spontaneous Phenotyping: Analysis of young (11–16 weeks) and aged (≥30 weeks) mice for lymphadenopathy, splenomegaly, and organ-specific inflammation (lung, skin, colon).
  • IL-33 Challenge: Systemic administration of IL-33 to induce acute expansion of ST2+ tissue-resident Tregs and Type 2 inflammation.
• Omics and Molecular Biology:
  • Single-cell RNA Sequencing (scRNA-seq): Performed on splenic CD45+ cells to characterize Treg subclusters and gene expression programs.
  • Bulk RNA Sequencing: Used on in vitro differentiated iTregs (iTregs) to identify differentially expressed genes.
  • Chromatin Immunoprecipitation Sequencing (ChIP-seq): Used to map IκBζ and BATF binding sites on chromatin in iTregs.
  • ChIP-qPCR: Validated binding of IκBζ and BATF to specific promoters (Il4, Il13, Batf).
• Immunological Assays:
  • Flow Cytometry: Phenotyping of Tregs, effector T cells, B cells, ILC2s, and eosinophils in various tissues.
  • In Vitro Suppression Assays: Measured the suppressive capacity of Tregs.
  • ELISA & Immunoblotting: Quantified cytokines (IL-4, IL-13) and detected autoantibodies (IgG1, IgE) in serum.
  • Histology: H&E, PAS (mucus), and Sirius Red (fibrosis) staining of lung and colon tissues.

3. Key Contributions

• Identification of IκBζ as a Molecular Switch: The study establishes IκBζ as a critical regulator that reprograms Tregs from immunosuppressive regulators into pathogenic, Th2-like effector cells.
• Mechanistic Link to BATF: The authors define a novel axis where IκBζ enhances the expression and chromatin occupancy of BATF, a transcription factor known to drive Th2 differentiation.
• Paradoxical Role of Treg Expansion: The study reveals that while Treg expansion is generally considered protective, the specific expansion driven by IκBζ (and IL-33) leads to a loss of tolerance and exacerbation of Type 2 inflammation.
• Therapeutic Implications: The findings suggest that interventions aimed at expanding tissue-resident Tregs (e.g., for fibrosis or GVHD) must carefully evaluate IκBζ induction to avoid inadvertently promoting inflammation.

4. Key Results

A. IκBζ Overexpression Drives Pathogenic Phenotypes

• Systemic Inflammation: Nfkbiz OEΔTreg mice developed severe lymphadenopathy and splenomegaly. Aged mice exhibited spontaneous dermatitis, colon inflammation, and severe lung pathology.
• Th2 Polarization: The lung pathology was characterized by goblet cell metaplasia, mucus hypersecretion, and fibrosis. There was a massive upregulation of Th2 cytokines (IL-4, IL-13) and a systemic shift toward Th2 immunity, evidenced by elevated serum IgE and IgG1 autoantibodies.
• Loss of Suppression: Despite maintaining FoxP3 expression, IκBζ-overexpressing Tregs showed reduced suppressive capacity in vitro.
• Cell-Intrinsic Reprogramming: scRNA-seq and bulk RNA-seq confirmed that IκBζ-overexpressing Tregs intrinsically upregulated Il4, Il13, and Batf, indicating a cell-autonomous conversion to a Th2-like phenotype rather than a secondary effect of effector T cells.

B. Mechanism: The IκBζ-BATF Axis

• Direct Regulation: ChIP-seq revealed that IκBζ binds directly to the promoters of Batf, Il4, and Il13.
• BATF Dependency: IκBζ overexpression increased BATF protein levels and its binding to the Il4 and Il13 promoters.
• Functional Validation: Treatment with a BATF/JUN inhibitor (T-5224) completely reversed the upregulation of Th2 cytokines in IκBζ-overexpressing Tregs, confirming that BATF is the essential downstream effector.
• Stability: Crucially, FoxP3 expression remained intact, suggesting IκBζ overrides canonical Treg stability mechanisms to drive this plasticity.

C. IκBζ Deletion Attenuates IL-33-Driven Inflammation

• IL-33 Response: In wild-type mice, IL-33 treatment induced IκBζ expression in ST2+ Tregs and caused massive expansion of these cells, accompanied by ILC2 expansion, eosinophilia, and lung inflammation.
• Protective Effect of KO: In Nfkbiz KOΔTreg mice, IL-33 treatment failed to expand ST2+ Tregs effectively. Surprisingly, this reduced Type 2 inflammation (less eosinophilia, lower ILC2 numbers, reduced cytokines) compared to controls.
• Interpretation: This suggests that IL-33-induced IκBζ is required to convert protective ST2+ Tregs into disease-promoting Th2-like cells. Without IκBζ, Tregs retain their suppressive function or fail to convert, thereby limiting inflammation.

5. Significance

• Redefining Treg Plasticity: The study challenges the dogma that Treg expansion is universally beneficial. It demonstrates that specific transcriptional programs (driven by IκBζ) can convert Tregs into "Trojan horses" that fuel Type 2 inflammation.
• Disease Relevance: The findings provide a mechanistic explanation for the presence of Th2-like Tregs in chronic inflammatory diseases like asthma, atopic dermatitis, and IBD, where IκBζ is often aberrantly expressed.
• Therapeutic Target: IκBζ is identified as a potential therapeutic target. Inhibiting IκBζ could stabilize Tregs and prevent their conversion into pathogenic effectors in Type 2 inflammatory diseases. Conversely, therapies expanding Tregs must ensure they do not induce IκBζ to avoid exacerbating autoimmunity or allergy.
• Autoimmunity Link: The discovery of IκBζ-driven autoantibody production (IgE/IgG1) links Treg dysfunction directly to systemic autoimmunity, expanding the understanding of Treg-related pathologies beyond simple loss of suppression.

In conclusion, this paper identifies IκBζ as a critical molecular switch that, via BATF, reprograms regulatory T cells into Th2-like effectors, driving systemic Type 2 inflammation and autoimmunity.